Section Arrow
UPB.NASDAQ
- Upstream Bio Inc
Quotes are at least 15-min delayed:2025/07/21 06:53 EDT
Pre Market
Last
 --
-- (--)
Bid
8.5
Ask
13.5
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 10.72
-0.32 (-2.90%)
Day High 
11.36 
Prev. Close
11.04 
1-M High
12.1 
Volume 
225.65K 
Bid
8.5
Ask
13.5
Day Low
10.63 
Open
11.11 
1-M Low
9.8233 
Market Cap 
593.88M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.29 
20-SMA 11.11 
50-SMA 10.34 
52-W High 29.4599 
52-W Low 5.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.67/-2.64
Enterprise Value
595.01M
Balance Sheet
Book Value Per Share
8.28
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.21M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.975 -0.305 -13.38%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.1 -0.975 -6.93%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.26 +0.42 +7.19%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.07 +0.15 +2.53%
Quotes are at least 15-min delayed:2025/07/21 06:53 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.